Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Highlights in Red Blood Cell Research
share announcement

Highlights in Red Blood Cell Research

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 31 May 2024 | Viewed by 1617

Special Issue Editors

Prof. Dr. Anna Bogdanova

E-Mail Website
Guest Editor
Red Blood Cell Research Group, Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zürich, Switzerland
Interests: red blood cells; hypoxia; heterogeneity; redox signaling; anemia
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Lars Kaestner

E-Mail Website
Guest Editor
Theoretical Medicine and Biosciences, Saarland University, Saarbruecken, Germany
Interests: red blood cells; ion channels; calcium signaling; microscopy; hematology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue welcomes articles exploring novel aspects of red blood cell research that address the following topics: (i) fundamental aspects of red blood cell structure and function; (ii) pathology associated with red blood cell disorders; (iii) red cell conservation, de novo production, and transfusion; and (iv) adaptation of red blood cells in humans and animals to environmental changes. We also welcome papers on novel technologies for studying red blood cells.

Prof. Dr. Anna Bogdanova
Prof. Dr. Lars Kaestner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • red blood cells
  • anemia
  • transfusion
  • erythropoiesis
  • signaling

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

24 pages, 5018 KiB  
Article
Hematin- and Hemin-Induced Spherization and Hemolysis of Human Erythrocytes Are Independent of Extracellular Calcium Concentration
by Diana M. Mikhailova, Elisaveta Skverchinskaya, Julia Sudnitsyna, Kirill R. Butov, Ekaterina M. Koltsova, Igor V. Mindukshev and Stepan Gambaryan
Cells 2024, 13(6), 554; https://doi.org/10.3390/cells13060554 - 21 Mar 2024
Viewed by 939
Abstract
Pathologies such as malaria, hemorrhagic stroke, sickle cell disease, and thalassemia are characterized by the release of hemoglobin degradation products from damaged RBCs. Hematin (liganded with OH−) and hemin (liganded with Cl−)—are the oxidized forms of heme with toxic [...] Read more.
Pathologies such as malaria, hemorrhagic stroke, sickle cell disease, and thalassemia are characterized by the release of hemoglobin degradation products from damaged RBCs. Hematin (liganded with OH−) and hemin (liganded with Cl−)—are the oxidized forms of heme with toxic properties due to their hydrophobicity and the presence of redox-active Fe3. In the present study, using the original LaSca-TM laser particle analyzer, flow cytometry, and confocal microscopy, we showed that both hematin and hemin induce dose-dependent RBC spherization and hemolysis with ghost formation. Hematin and hemin at nanomolar concentrations increased [Ca2+]i in RBC; however, spherization and hemolysis occurred in the presence and absence of calcium, indicating that both processes are independent of [Ca2+]i. Both compounds triggered acute phosphatidylserine exposure on the membrane surface, reversible after 60 min of incubation. A comparison of hematin and hemin effects on RBCs revealed that hematin is a more reactive toxic metabolite than hemin towards human RBCs. The toxic effects of heme derivatives were reduced and even reversed in the presence of albumin, indicating the presence in RBCs of the own recovery system against the toxic effects of heme derivatives. Full article
(This article belongs to the Special Issue Highlights in Red Blood Cell Research)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 1519 KiB  
Review
Current and Future Therapeutics for Treating Patients with Sickle Cell Disease
by Mariam Barak, Christopher Hu, Alicia Matthews and Yolanda M. Fortenberry
Cells 2024, 13(10), 848; https://doi.org/10.3390/cells13100848 - 16 May 2024
Viewed by 367
Abstract
Sickle cell disease (SCD) is the most common genetic blood disorder in the United States, with over 100,000 people suffering from this debilitating disease. SCD is caused by abnormal hemoglobin (Hb) variants that interfere with normal red blood cell (RBC) function. Research on [...] Read more.
Sickle cell disease (SCD) is the most common genetic blood disorder in the United States, with over 100,000 people suffering from this debilitating disease. SCD is caused by abnormal hemoglobin (Hb) variants that interfere with normal red blood cell (RBC) function. Research on SCD has led to the development and approval of several new SCD therapies in recent years. The recent FDA-approved novel gene therapies are potentially curative, giving patients an additional option besides a hematopoietic bone marrow transplant. Despite the promise of existing therapies, questions remain regarding their long-term pharmacological effects on adults and children. These questions, along with the exorbitant cost of the new gene therapies, justify additional research into more effective therapeutic options. Continual research in this field focuses on not only developing cheaper, more effective cures/treatments but also investigating the physiological effects of the current therapies on SCD patients, particularly on the brain and kidneys. In this article, we undertake a comprehensive review of ongoing clinical trials with completion dates in 2024 or later. Our exploration provides insights into the landscape of current therapeutics and emerging novel therapies designed to combat and potentially eradicate SCD, including the latest FDA-approved gene therapies. Full article
(This article belongs to the Special Issue Highlights in Red Blood Cell Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop